EUVIMEDEUVIMED entdecken
Crossref

CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer

Dongdong Wang, Guozhi Zhou

Int. Journal of Clinical Pharmacology and Therapeutics · 09.11.2026

DOI: 10.5414/cp205039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 09.11.2026. Verfasst von Dongdong Wang und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Wang, D., & Zhou, G. (2026). CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp205039

Vancouver

Wang D, Zhou G. CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer. Int. Journal of Clinical Pharmacology and Therapeutics. 2026. doi:10.5414/cp205039

BibTeX
@article{Wang2026,
  author = {Wang, Dongdong and Zhou, Guozhi},
  title = {CD14 monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.5414/cp205039}
}
Kostenlos starten →